Key result
Renal denervation (RDN) achieved a responder rate of 89.5% compared to 51.9% in the control group at 12 months post-procedure.
Why the study?
Renal denervation lowers SBP in essential hypertension, but patient selection among those taking medications remains an unmet clinical need.
Does the presence of preprocedural features associated with increased renin-angiotensin-aldosterone activity improve the response to renal denervation in patients with uncontrolled hypertension?
Observational (n=46)
Yes
Does the presence of preprocedural features associated with increased renin-angiotensin-aldosterone activity improve the response to renal denervation in patients with uncontrolled hypertension?
Effect estimate: RR 1.73 (95% CI 1.24-2.42)
Absolute Event Rate: 89.5% vs 51.9%
p-value: p=<0.001
Preprocedural features indicating increased renin-angiotensin-aldosterone activity may help identify patients with uncontrolled hypertension who are more likely to respond to renal denervation.
Preprocedural RAAS markers may identify RDN responders in uncontrolled hypertension; leaves open confirmation in randomized trials.
Background: Renal denervation (RDN) is effective to lower systolic blood pressure (SBP) in essential hypertension. However, patient selection under medications remains an important unmet clinical need. Methods: This multicenter study aimed at observing whether preprocedural features associated with increased renin-angiotensin-aldosterone activity influence RDN response. This study enrolled the patients who underwent RDN for uncontrolled hypertension. Medical records were reviewd and patients were divided into 2 groups depending by meeting any of the following conditions prior to RDN: (1) >10 mmHg of office SBP reduction after aldosterone inhibition, (2) aldosterone-renin ratio >30 or (3) slow flow on the renal angiogram. RDN responders were defined by a reduction in 24-hour mean ≥6 mmHg or by ≥1 class of antihypertensive drug withdraw. Results: A total of 46 patients were enrolled, of which 27 (59%) were in control group A and 19 (41%) in group B. The baseline age, gender, office and 24-hour SBP (mean 140.0 ± 12.8 mmHg vs. 144.0 ± 16.5 mmHg, p = 0.577) were comparable, while the number of prescribed drug classes was fewer in group A (4.0 ± 1.3 vs. 4.9 ± 0.9, p = 0.014). The proportion patients with prescribed aldosterone antagonist or high aldosterone-renin ratios were higher in group B. At 12 months post RDN, the results were significantly better in group B in terms of mean change in office SBP (12.4 ± 23.5 mmHg vs. 29.9 ± 25.5 mmHg, p = 0.046) and the proportion of RDN responders (51.9% vs. 89.5%, p < 0.001). Conclusion: RDN was more effective in patients with any of 3 clinical indices.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2022) conducted an observational in uncontrolled hypertension (n=46). Renal denervation (RDN) vs. Control group (group A) was evaluated on Proportion of responders to RDN (RR 1.73, 95% CI 1.24-2.42, p=<0.001). Renal denervation (RDN) achieved a responder rate of 89.5% compared to 51.9% in the control group at 12 months post-procedure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: